These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9134269)

  • 1. Low molecular weight heparin for acute ischemic heart disease.
    Conti CR
    Clin Cardiol; 1997 May; 20(5):415-6. PubMed ID: 9134269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low molecular weight heparins in acute coronary syndrome].
    Huber K; Niessner A; Niessner H
    Herz; 2001 Apr; 26 Suppl 1():53-60. PubMed ID: 11349628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
    Borja J; Olivella P
    Med Clin (Barc); 2000 Nov; 115(15):583-6. PubMed ID: 11141394
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-molecular weight heparins.
    Talley JD
    J Ark Med Soc; 1997 Apr; 93(11):555-6. PubMed ID: 9114648
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine].
    Manganaro A; Giannino D; Lembo D; Bruni F; Consolo F
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):41-51. PubMed ID: 11253339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    Kaul S; Shah PK
    J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective use of fondaparinux in patient with unresponsiveness to nadroparin.
    Hartinger JM; Svobodová A; Malíková I; Šachl R; Slanař O
    J Clin Pharm Ther; 2021 Apr; 46(2):539-542. PubMed ID: 33277918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of unstable angina with the low molecular weight heparins.
    Ageno W; Turpie AG
    Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report.
    Rydzewska-Rosolowska A; Borawski J; Mysliwiec M
    Adv Med Sci; 2009; 54(2):199-202. PubMed ID: 19758969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of low-molecular-weight heparin in the management of acute coronary syndromes.
    Cohen M
    Curr Opin Cardiol; 2001 Nov; 16(6):384-9. PubMed ID: 11704710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New anticoagulants in ischemic heart disease.
    Verheugt FW
    Presse Med; 2005 Oct; 34(18):1325-9. PubMed ID: 16269997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin in unstable coronary artery disease.
    Wallentin L
    Expert Opin Investig Drugs; 2000 Mar; 9(3):581-92. PubMed ID: 11060697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF; Hull RD
    Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparins in acute coronary syndrome.
    Creekmore F
    S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862
    [No Abstract]   [Full Text] [Related]  

  • 18. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of perioperative low-molecular-weight heparin therapy on clinical events of elderly patients with prior coronary stents implanted > 12 months undergoing non-cardiac surgery: a randomized, placebo-controlled trial.
    Wang B; Su Y; Ma C; Xu L; Mao Q; Cheng W; Lu Q; Zhang Y; Wang R; Lu Y; He J; Chen S; Chen L; Li T; Gao L
    BMC Med; 2024 Apr; 22(1):171. PubMed ID: 38649992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?].
    Panchenko EP
    Ter Arkh; 1998; 70(12):71-4. PubMed ID: 10067259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.